Cumberland Pharmaceuticals Inc.
CPIX
$5.72
-$0.14-2.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -22.04% | 4.92% | -8.73% | 10.04% | 37.84% |
| Total Other Revenue | -- | 210.12% | -- | -- | -- |
| Total Revenue | -22.04% | 31.08% | -8.73% | 10.04% | 37.84% |
| Cost of Revenue | 35.65% | 13.40% | -25.26% | 17.56% | -9.51% |
| Gross Profit | -30.04% | 35.21% | -5.92% | 8.46% | 48.61% |
| SG&A Expenses | 13.81% | 35.72% | -0.95% | 1.33% | 2.64% |
| Depreciation & Amortization | 24.23% | -30.57% | -6.37% | -8.49% | -9.49% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.65% | 22.58% | -4.85% | 6.52% | 0.52% |
| Operating Income | -342.22% | 25.56% | -15.99% | 27.19% | 169.11% |
| Income Before Tax | -361.84% | 28.24% | -27.39% | 33.15% | 166.31% |
| Income Tax Expenses | -31.58% | 140.70% | -50.00% | -50.00% | -50.00% |
| Earnings from Continuing Operations | -363.35% | 24.87% | -26.81% | 33.32% | 165.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -129.21% | 872.73% | 216.90% | -132.35% | 120.32% |
| Net Income | -361.68% | 25.85% | -25.69% | 31.77% | 164.59% |
| EBIT | -342.22% | 25.56% | -15.99% | 27.19% | 169.11% |
| EBITDA | -179.75% | 4.72% | -60.36% | 153.90% | 423.34% |
| EPS Basic | -361.47% | 30.74% | -18.02% | 35.63% | 160.90% |
| Normalized Basic EPS | -347.55% | 34.40% | -2.15% | 34.61% | 160.99% |
| EPS Diluted | -375.00% | 32.67% | -18.18% | 37.50% | 157.14% |
| Normalized Diluted EPS | -352.79% | 34.40% | -2.15% | 34.61% | 159.72% |
| Average Basic Shares Outstanding | 0.12% | 7.05% | 6.44% | 5.97% | 5.99% |
| Average Diluted Shares Outstanding | -1.96% | 7.05% | 6.44% | 5.97% | 8.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |